共 50 条
- [1] Mortality and Causes of Death of Patients with Polycythemia Vera: Analysis of the REVEAL Prospective, Observational Study CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 : S355 - S355
- [3] Characteristics and Clinical Outcomes in Patients With Polycythemia Vera Receiving Ruxolitinib After Hydroxyurea: A Longitudinal Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices Trial (REVEAL) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S404 - S405
- [4] A Real-World Evaluation of Risk Factors for Disease Progression in Patients With Polycythemia Vera (PV): An Analysis From the Prospective Observational Study of Patients With Polycythemia Vera in US Clinical Practices (REVEAL) CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S415 - S416
- [6] Clinical and Disease Characteristics From REVEAL at Time of Enrollment (Baseline): Prospective Observational Study of Patients With Polycythemia Vera in the United States CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (12): : 788 - +
- [8] INFLUENCE OF THERAPY ON CAUSES OF DEATH IN POLYCYTHEMIA-VERA TRANSACTIONS OF THE ASSOCIATION OF AMERICAN PHYSICIANS, 1981, 94 : 30 - 38
- [9] INFLUENCE OF THERAPY ON CAUSES OF DEATH IN POLYCYTHEMIA-VERA CLINICAL RESEARCH, 1981, 29 (02): : A573 - A573
- [10] Patient-Reported Outcomes Data From REVEAL at the Time of Enrollment (Baseline): A Prospective Observational Study of Patients With Polycythemia Vera in the United States CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (09): : 590 - 596